Longeveron Inc.
Longeveron is a global leader in stem cell therapies, developing regenerative medicine solutions for life-threatening and aging-related conditions. The company's mission is to improve healthspan through innovative cell-based therapeutics, with a focus on diseases such as Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and Aging Frailty. With a strong research pipeline, clinical trials, and a state-of-the-art GMP manufacturing facility, Longeveron aims to bring safe and effective regenerative treatments to patients worldwide.
Industries
Nr. of Employees
small (1-50)
Longeveron Inc.
Life Science & Technology Park, 1951 NW 7th Avenue, Suite 520, Miami, FL 33136
Patents
Mesenchymal stem cells as vaccine adjuvants and methods for using the same
US-11975068-B2
View Details
Mesenchymal stem cells as vaccine adjuvants and methods for using the same
US-11975068-B2
View DetailsProducts
Allogeneic bone-marrow-derived mesenchymal stromal cell therapeutic candidate
Investigational allogeneic MSC product manufactured via culture expansion, formulated and cryopreserved for clinical use across indications including congenital heart disease (HLHS), neurodegeneration (Alzheimer’s), aging-related frailty, ARDS and metabolic syndrome.
Allogeneic bone-marrow-derived mesenchymal stromal cell therapeutic candidate
Investigational allogeneic MSC product manufactured via culture expansion, formulated and cryopreserved for clinical use across indications including congenital heart disease (HLHS), neurodegeneration (Alzheimer’s), aging-related frailty, ARDS and metabolic syndrome.
Services
Facility-based contract development and manufacturing services for preclinical and clinical cell therapy programs including process development, analytical/QC testing and cGMP clinical manufacturing.
Sponsorship and operational management of multi-phase clinical studies and treatment registry programs, including randomized and controlled trial execution and long-term follow-up data collection.
On-site laboratory analytical testing and assay support for cell therapy development, including flow cytometry, molecular assays, immunoassays and rapid microbiological testing to support lot release.
Facility-based contract development and manufacturing services for preclinical and clinical cell therapy programs including process development, analytical/QC testing and cGMP clinical manufacturing.
Sponsorship and operational management of multi-phase clinical studies and treatment registry programs, including randomized and controlled trial execution and long-term follow-up data collection.
On-site laboratory analytical testing and assay support for cell therapy development, including flow cytometry, molecular assays, immunoassays and rapid microbiological testing to support lot release.
Expertise Areas
- cGMP cell therapy manufacturing
- Process development and scale-up for cell therapeutics
- Clinical trial management and registry operations
- Regulatory strategy for biologics and cell therapies
Key Technologies
- Mesenchymal stromal cell culture and expansion
- Cryopreservation and frozen-chain logistics
- Flow cytometry
- PCR / qRT-PCR
News & Updates
Longeveron was selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy laromestrocel (Lomecel-B™), evaluated as a potential treatment for Alzheimer’s disease and Hypoplastic Left Heart Syndrome.
The trial results are anticipated in Q3 2026, with potential BLA submission if results are positive. The program has received FDA designations including Rare Pediatric Disease, Orphan Drug, and Fast Track.
Longeveron was recognized for its innovative stem cell therapy laromestrocel (Lomecel-B™) in the field of healthspan extension.
Longeveron was selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy laromestrocel (Lomecel-B™), evaluated as a potential treatment for Alzheimer’s disease and Hypoplastic Left Heart Syndrome.
The trial results are anticipated in Q3 2026, with potential BLA submission if results are positive. The program has received FDA designations including Rare Pediatric Disease, Orphan Drug, and Fast Track.
Longeveron was recognized for its innovative stem cell therapy laromestrocel (Lomecel-B™) in the field of healthspan extension.